Chimerix, Inc. (NASDAQ:CMRX) Position Increased by Stoneridge Investment Partners LLC

Stoneridge Investment Partners LLC boosted its stake in Chimerix, Inc. (NASDAQ:CMRX) by 22.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,305 shares of the biopharmaceutical company’s stock after buying an additional 8,134 shares during the period. Stoneridge Investment Partners LLC’s holdings in Chimerix were worth $154,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Valeo Financial Advisors LLC increased its holdings in shares of Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 69,505 shares during the period. Marshall Wace LLP acquired a new stake in shares of Chimerix in the second quarter valued at approximately $137,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 138,098 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock worth $2,846,000 after buying an additional 496,823 shares during the period. 45.42% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on CMRX shares. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Chimerix in a research report on Monday, December 30th. Wedbush reissued an “outperform” rating and set a $6.00 price target on shares of Chimerix in a report on Tuesday, December 10th.

Chimerix Price Performance

NASDAQ CMRX opened at $4.21 on Friday. Chimerix, Inc. has a 12 month low of $0.75 and a 12 month high of $4.30. The firm has a market capitalization of $378.65 million, a PE ratio of -4.48 and a beta of 0.35. The company’s 50 day simple moving average is $3.18 and its 200 day simple moving average is $1.70.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $1.26 million. During the same period in the prior year, the firm posted ($0.27) earnings per share. Sell-side analysts anticipate that Chimerix, Inc. will post -0.99 earnings per share for the current fiscal year.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.